FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:541-542 January 29, 2009 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Steinberg, D. PubMed Citation

To the Editor: In his Perspective article, Steinberg (Oct. 2 issue)¹ cites the largest meta-analysis to date of the statin class of pharmaceutical agents.² The range he cites as the relative risk reduction for all-cause mortality, 20 to 30%, is inaccurate. The relative risk reduction was 12% over 5 years. This number means that one death per year was averted for every 417 patients taking a statin drug, or 1 of every 83 patients after 5 years of therapy. The large preponderance of subjects in this meta-analysis had established coronary disease, and the mortality rate among subjects in the control . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.